SureTrader Nadex Advertisement SureTrader
Home > Boards > US Listed > Biotechs >

Aurinia Pharmaceuticals Inc (AUPH)

AUPH RSS Feed
Add AUPH Price Alert      Hide Sticky   Hide Intro
Moderator: reconranger, Jesspro, jimbosskow
Search This Board: 
Last Post: 4/23/2017 12:03:13 AM - Followers: 124 - Board type: Free - Posts Today: 1

Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need.

*Aurinia Pharmaceuticals Inc.
http://www.auriniapharma.com/
 

Pipeline

 

Pipeline

Pipeline

Candidate & Indication Development Stage
Preclinical Phase 1 Phase 2 Phase 3 Market
VOCLOSPORINLupus Nephritis (LN)
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Market Phase not started

Aurinia is committed to working in areas of high unmet medical need and is poised to deliver the first approved therapy in the U.S. and Europe for the treatment of lupus nephritis, or LN.

The Voclosporin Advantage

Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data in over 2,000 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus nephritis (LN) when added to standard of care mycophenolate mofetil (MMF). It has been granted “fast track status” by the U.S. Food & Drug Administration (FDA).

Voclosporin Could Transform the LN treatment Landscape

Voclosporin has the potential to become a best in class medication and the first approved treatment for LN in the U.S. and Europe, effectively altering the current treatment paradigm for the disease.

Advantages of Voclosporin Combined with Standard of Care (SoC)

Our clinical data suggests that adding voclosporin to the current SoC of MMF for the treatment of lupus nephritis (LN) will yield superior results to using the standard of care alone.

Additionally, voclosporin may prove to be an ideal therapy for lupus nephritis due to advantages such as:

  • Improved efficacy
    Increased safety
    Oral administration
    Improved average time to renal response or remission
    Improved duration of renal response
    Reduction in steroid burden
    Potential first line add-on to MMF
    Fewer toxic immunosuppressants required
Benefits of Voclosporin

Potential Benefits of Voclosporin

In clinical trials, Voclosporin has been shown to be especially effective in the presence of low dose steroids with rapid reduction of LN inflammatory markers and overall improved renal stability.

The list of potential product benefits includes:

LN Critical Need Voclosporin (based on AURA Results)
Control of Active Disease
Rapid Disease Control
Lower Steroid Burden
Impact on Extra-renal disease
Convenient Treatment Regimen

In previous studies, over 2000 patients have been treated with Voclosporin with no abnormal or unexpected SAE’s

Well Characterized Safety Profile

Efficacy of calcineurin inhibition has already been established. Voclosporin has a well-characterized safety profile (over 2,000 patient exposures across multiple years) across indications.

No new safety signals were observed with the use of Voclosporin in LN patients; Voclosporin was well-tolerated and renal function remained stable in clinical studies. The overall safety profile is consistent with other immunosuppressive drugs.

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AUPH
Current Price
Volume:
Bid Ask Day's Range
SureTrader
PostSubject
#2943  Sticky Note There is a faction on another public forum puravida 04/22/17 04:20:15 PM
#576  Sticky Note To everyone. Please keep your posts talking about jimbosskow 01/30/17 04:31:08 AM
#2961   $AUPH VERY LONG . Another factor will be POSSIBILITIES 04/23/17 12:03:13 AM
#2960   Been out riding today, It is nice to cervelo 04/22/17 10:45:27 PM
#2959   We will look back at these posts in vidpok45 04/22/17 10:18:34 PM
#2958   Excellent synopsis of the priority catalysts for AUPH. the gipper 04/22/17 09:49:28 PM
#2957   Puravida, follow the share price action and not biotech_researcher 04/22/17 09:27:32 PM
#2956   I also wouldn't be surprised to see them Lunacy 04/22/17 07:56:52 PM
#2955   Great post! I completely agree that there Lunacy 04/22/17 07:31:42 PM
#2954   Great! Good luck to us both with AUPH! nferna 04/22/17 06:30:54 PM
#2953   I'm young, trust me, it's not an absurd historyperson 04/22/17 06:19:53 PM
#2952   I agree with what you and others are nferna 04/22/17 06:03:55 PM
#2951   Just read your post again. Great research, invaluable. vidpok45 04/22/17 05:40:14 PM
#2950   A great deal of reassuring information on your yankees7 04/22/17 05:23:02 PM
#2949   The shorts can only bring down this Jesspro 04/22/17 04:36:35 PM
#2948   Your post should be read by every investor. vidpok45 04/22/17 04:33:39 PM
#2947   That was my same thought as well. Lunacy 04/22/17 04:32:40 PM
#2946   Excellent DD. How do we pin this message? JKM1 04/22/17 04:30:10 PM
#2945   sounds right. Except a good deal for vidpok45 04/22/17 04:29:52 PM
#2944   Nice post. Learned a lot. Awlau 04/22/17 04:28:15 PM
#2943   There is a faction on another public forum puravida 04/22/17 04:20:15 PM
#2942   Regarding Glickman’s statement on 4/20, that “greater value Eileen3 04/22/17 04:10:07 PM
#2941   It will be marvelous. On we fight. historyperson 04/22/17 03:56:27 PM
#2940   I just happened to see the short interest althegambler 04/22/17 03:55:06 PM
#2939   You said that perfectly. This is a vidpok45 04/22/17 03:51:46 PM
#2938   vid, I and many others went thru a althegambler 04/22/17 03:38:30 PM
#2937   You just stated much more succinctly what took vidpok45 04/22/17 03:14:35 PM
#2936   Please note that diversification across various stocks in vidpok45 04/22/17 03:11:25 PM
#2935   I've heard it said that diversification is to rumrunner528 04/22/17 03:10:32 PM
#2934   I think "diversification" is a concept developed by vidpok45 04/22/17 02:59:06 PM
#2933   Well said Vidpok. The orchestrated daily manipulations are ThePromise247 04/22/17 02:50:34 PM
#2932   Thanks for the encouragement TC. The "believer" part historyperson 04/22/17 02:01:12 PM
#2931   TC, this board, like other Ihub boards is vidpok45 04/22/17 10:59:22 AM
#2930   Hi Vid et al, a few quick things here... trading_cyclist 04/22/17 08:41:10 AM
#2929   I dont think Glickman would sell the company vidpok45 04/22/17 07:16:45 AM
#2928   Is Eeyore a fair weather character? Probably not, Jesspro 04/22/17 06:16:51 AM
#2926   Cantor Fitzgerald reiterates buy on Aurinia P. Jesspro 04/21/17 11:23:29 PM
#2925   And i would think after the manipulation in cervelo 04/21/17 07:51:42 PM
#2924   Not going after EU & Japanese deals leads Lunacy 04/21/17 07:45:38 PM
#2923   That is what I thought, which made me cervelo 04/21/17 07:39:39 PM
#2922   52 weeks. Fully blinded until completion. Lunacy 04/21/17 07:37:38 PM
#2921   is phase 3 a 1 or 2 year trial? cervelo 04/21/17 07:31:26 PM
#2919   I wholeheartedly agree. I can't even remember Lunacy 04/21/17 07:15:18 PM
#2918   Usually, this is not a good sign: "Right now biotech_researcher 04/21/17 07:15:16 PM
#2917   We just had as good a report as vidpok45 04/21/17 06:53:48 PM
#2915   That might happen as soon as Monday, so Lunacy 04/21/17 06:06:51 PM
#2914   Next event that will drive AUPH higher will greggors 04/21/17 06:00:15 PM
#2913   Get used to it. May have vidpok45 04/21/17 05:21:47 PM
#2912   Not sure how it all works but change wilco244 04/21/17 05:20:11 PM
#2911   I'm curious as to how it actually works historyperson 04/21/17 05:15:43 PM
#2910   I have always had a hard time understanding IndianaUSA 04/21/17 05:01:14 PM
#2909   I thought that all that have to do CaptainObvious2017 04/21/17 04:50:12 PM
PostSubject